Name: Vanflyta
Indications: To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria.
Active Ingredient: Quizartinib
Company: Daiichi Sankyo, Inc
Approval Date: 7/20/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216993s000lbl.pdf